If you read the PRs IPIX has indicated it has been talking to other companies for months. At this point there is no way to value Brilacidin for Covid until we know how it works in the human trials.
The pre clinical in vitro testing and SI number indicates Brilacidin is one of the best if not the best antiviral tested. IPIX shareholders also know Brilacidin has been safe in preceding trials. The in vitro tests suggest Brilacidin will be used at a lower dose in the clinical trials. IPIX shareholders have reason to be optimistic.
The human Phase 2 clinical trials interim report will tell us a lot. Anti-infective clinical trials are generally short.
After a few weeks IPIX will know how Brilacidin clears the virus, lowers the viral load. It will know how it reduces the acute signs of infection. It will start to have an idea how it lowers the progression to pulmonary failure and other systemic complications.
By the end of the phase 2 trial IPIX should be able to report some mortality, morbidity statistics. Or, like Remdesivir we should be able to show a reduced time to discharge or Regeneron we may report a diminished number of health care visits.
If the Phase 2 trials are successful IPIX will have a number of options on how to proceed. They could have funding to go it alone, but I am not sure they have the corporate structure to successfully administer what has to be a worldwide distribution.I think it is more likely IPIX will partner or license the rights for distribution to several companies based on their partners geographic dominance. IPIX does not have to agree to terms after the Phase 2 trial; it will have time to pick and chose before the Phase 3 trial is completed. An EUA in January may force their hand to partner or bulk up to be a much bigger company.
Time will tell. The above is just an example of how Brilacin's course might go.Of course many factors will influence the final outcome and it most likely will be different from my projections.
GLTA, Farrell
News 
Market Data 
Discover 
